Status:
COMPLETED
Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer
Lead Sponsor:
University Hospital, Bordeaux
Collaborating Sponsors:
University of Bordeaux
Conditions:
Bladder Cancer
Eligibility:
All Genders
Brief Summary
Non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence (60 to 70%) and progression (20 to 30%) to muscle-invasive bladder cancer (MIBC). The local immunotherapy (intra-vesical Bacil...
Detailed Description
Non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence (60 to 70%) and progression (20 to 30%) to muscle-invasive bladder cancer (MIBC). The local immunotherapy (intra-vesical Bacil...
Eligibility Criteria
Inclusion
- Patients with histologically documented normal bladder, NMIBC (Ta, T1, CIS) or MIBC stored in the tissue bank.
- Samples collected from 2007 to 2011. 3 years follow-up is mandatory to assess the frequency of recurrences and progressions.
Exclusion
- History of autoimmune disease
- Active tuberculosis
- Prior treatment with CD137 agonists, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Key Trial Info
Start Date :
March 16 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 14 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04726735
Start Date
March 16 2020
End Date
May 14 2020
Last Update
January 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de Bordeaux
Talence, France